ATE328083T1 - Menschlicher bikunin - Google Patents

Menschlicher bikunin

Info

Publication number
ATE328083T1
ATE328083T1 AT97915029T AT97915029T ATE328083T1 AT E328083 T1 ATE328083 T1 AT E328083T1 AT 97915029 T AT97915029 T AT 97915029T AT 97915029 T AT97915029 T AT 97915029T AT E328083 T1 ATE328083 T1 AT E328083T1
Authority
AT
Austria
Prior art keywords
human bikunin
bikunin
human
Prior art date
Application number
AT97915029T
Other languages
German (de)
English (en)
Inventor
Paul P Tamburini
Gary Davis
Katherine A Delaria
Christopher W Marlor
Daniel K Muller
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Application granted granted Critical
Publication of ATE328083T1 publication Critical patent/ATE328083T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
AT97915029T 1996-03-11 1997-03-10 Menschlicher bikunin ATE328083T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1310696P 1996-03-11 1996-03-11
US1979396P 1996-06-14 1996-06-14
US72525196A 1996-10-04 1996-10-04

Publications (1)

Publication Number Publication Date
ATE328083T1 true ATE328083T1 (de) 2006-06-15

Family

ID=27359773

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97915029T ATE328083T1 (de) 1996-03-11 1997-03-10 Menschlicher bikunin

Country Status (27)

Country Link
US (3) US6583108B1 (en:Method)
EP (1) EP0891426B1 (en:Method)
JP (2) JP3469584B2 (en:Method)
KR (1) KR100356956B1 (en:Method)
AR (3) AR006188A1 (en:Method)
AT (1) ATE328083T1 (en:Method)
AU (1) AU716923B2 (en:Method)
BR (1) BR9708021A (en:Method)
CA (1) CA2247888A1 (en:Method)
CO (1) CO4600683A1 (en:Method)
DE (1) DE69735996T2 (en:Method)
DK (1) DK0891426T3 (en:Method)
ES (1) ES2263174T3 (en:Method)
HR (1) HRP970144B1 (en:Method)
HU (1) HU226419B1 (en:Method)
ID (1) ID16224A (en:Method)
IL (1) IL126115A (en:Method)
IN (1) IN192874B (en:Method)
MY (1) MY120693A (en:Method)
NZ (1) NZ331540A (en:Method)
PA (1) PA8426301A1 (en:Method)
PL (1) PL188387B1 (en:Method)
PT (1) PT891426E (en:Method)
SV (1) SV1997000018A (en:Method)
TR (1) TR199801794T2 (en:Method)
WO (1) WO1997033996A2 (en:Method)
YU (1) YU8997A (en:Method)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
EP0758682B1 (en) * 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
BR9708021A (pt) 1996-03-11 1999-07-27 Bayer Ag Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína
AU6042298A (en) * 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
ES2318075T3 (es) * 1998-12-22 2009-05-01 Bayer Aktiengesellschaft Metodo para acelerar la velocidad de eliminacion mucociliar.
US7704958B1 (en) 1999-03-05 2010-04-27 Bio Holding, Inc. Methods and compositions for inhibiting apoptosis using serine protease inhibitors
US6489308B1 (en) 1999-03-05 2002-12-03 Trustees Of University Of Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
IL140994A (en) * 2000-05-15 2005-12-18 Bayer Ag Urinary trypsin inhibitor assay containing a chelating agent
IL140993A0 (en) 2000-05-15 2002-02-10 Bayer Ag Trypsin substrate and diagnostic device, and method of using same
US6955921B2 (en) * 2001-04-30 2005-10-18 Bayer Corporation Trypsin substrate and diagnostic device, and method of using same
CA2460653A1 (en) * 2001-11-05 2003-05-15 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE512674T1 (de) 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
WO2005019434A2 (en) 2003-08-26 2005-03-03 The Regents Of The University Of Colorado, A Body Corporate Serine protease inhibitors for treatment of bacterial infections
JP2007518426A (ja) * 2003-10-10 2007-07-12 マルチセル テクノロジーズ、インコーポレイテッド 不死化肝細胞
US7419665B2 (en) * 2003-10-16 2008-09-02 Siemens Healthcare Diagnostics Inc. Monoclonal antibodies for detection of urinary trypsin inhibitors
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
CA3090413C (en) 2004-06-04 2023-10-10 Abbott Diabetes Care Inc. Glucose monitoring and graphical representations in a data management system
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
PL2360258T3 (pl) 2005-02-18 2015-03-31 Angiochem Inc Polipeptydy aprotyniny do transportowania związków przez barierę krew-mózg
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
DK2233156T3 (da) 2005-07-15 2013-08-05 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
US8093017B2 (en) 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
AU2006332774A1 (en) 2005-12-29 2007-07-12 Dyax Corp. Protease inhibition
AU2007299562A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor
WO2008058167A2 (en) * 2006-11-07 2008-05-15 Case Western Reserve University Method for treating disorders associated with complement activation
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2170932A4 (en) * 2007-06-20 2012-10-10 Phylogica Ltd COMPOSITIONS AND APPLICATIONS THEREOF IN THE TREATMENT OF ACUTE ATOMIC SYNDROME (ARDS) AND ASSOCIATED CLINICAL ILLNESSES
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
WO2009127072A1 (en) * 2008-04-18 2009-10-22 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
WO2010043049A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
AU2009304560A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of GLP-1 agonists and uses thereof
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
AU2010239069B2 (en) 2009-04-20 2015-05-14 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
HUE039605T2 (hu) 2010-01-06 2019-01-28 Dyax Corp Plazma kallikreint kötõ proteinek
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
JP6216921B2 (ja) 2011-06-24 2017-11-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１抗トリプシン融合分子のための組成物、方法および使用
EP2802653A4 (en) 2012-01-10 2015-09-02 Univ Colorado Regents COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
WO2014026283A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
SI3110434T1 (sl) 2014-02-24 2019-02-28 Takeda Gmbh UTI fuzijski proteini
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
KR20250139401A (ko) 2015-12-11 2025-09-23 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
BR112022017718A2 (pt) 2020-03-05 2022-11-16 Diamedica Usa Inc Polipeptídeos de ulinastatina

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
DE59007737D1 (de) 1989-05-13 1995-01-05 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel.
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
DK0439442T3 (da) 1990-01-25 1996-07-08 Univ Washington Faktor X-LACI-hybridprotein
ATE243710T1 (de) 1991-03-01 2003-07-15 Dyax Corp Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
EP0651766A4 (en) 1992-07-13 1996-07-31 Corvas Int Inc INHIBITORS OF FACTOR Xa, DERIVED FROM THE INHIBITOR OF THE PANCREATIC TRYPSON FROM BEEF.
US5436153A (en) 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
EP0740702A1 (en) 1992-12-02 1996-11-06 Zymogenetics, Inc. Novel human amyloid protein precursor homologue and kunitz-type inhibitors
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
PT1489097E (pt) 1994-01-11 2012-01-04 Dyax Corp Inibidores de plasmina humana derivados de domínios kunitz e ácidos nucleicos codificando os mesmos
US5795865A (en) 1994-01-11 1998-08-18 Dyax Corp. Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
WO1996003503A1 (en) 1994-07-21 1996-02-08 The Green Cross Corporation Process for producing urinary trypsin inhibitor and domains thereof, novel polypeptide related to the both, and process for producing the polypeptide
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
KR19990008458A (ko) 1995-05-08 1999-01-25 쉬어러 피터 알. 쿠니츠(kunitz) 타입 프로테아제 억제 물질
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
EP0758682B1 (en) 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
BR9708021A (pt) 1996-03-11 1999-07-27 Bayer Ag Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína
AU6042298A (en) 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity

Also Published As

Publication number Publication date
JP2004000208A (ja) 2004-01-08
JP2001521367A (ja) 2001-11-06
DK0891426T3 (da) 2006-10-02
KR100356956B1 (ko) 2003-03-15
US6583108B1 (en) 2003-06-24
TR199801794T2 (xx) 2000-07-21
CA2247888A1 (en) 1997-09-18
HUP9902698A3 (en) 2001-06-28
US7019123B2 (en) 2006-03-28
HU226419B1 (en) 2008-12-29
DE69735996D1 (de) 2006-07-06
US7452859B2 (en) 2008-11-18
IN192874B (en:Method) 2004-05-29
YU8997A (sh) 1999-09-27
US20030194398A1 (en) 2003-10-16
US20060172946A1 (en) 2006-08-03
PT891426E (pt) 2006-10-31
AR053063A2 (es) 2007-04-18
NZ331540A (en) 1999-10-28
ES2263174T3 (es) 2006-12-01
HRP970144A2 (en) 1998-04-30
WO1997033996A3 (en) 1997-11-13
IL126115A (en) 2007-03-08
PL188387B1 (pl) 2005-01-31
PL328822A1 (en) 1999-02-15
BR9708021A (pt) 1999-07-27
AR006188A1 (es) 1999-08-11
AR058982A1 (es) 2008-03-05
CO4600683A1 (es) 1998-05-08
EP0891426B1 (en) 2006-05-31
JP3469584B2 (ja) 2003-11-25
HRP970144B1 (en) 2004-10-31
KR19990087697A (ko) 1999-12-27
EP0891426A2 (en) 1999-01-20
DE69735996T2 (de) 2007-02-15
PA8426301A1 (es) 2000-05-24
AU716923B2 (en) 2000-03-09
WO1997033996A2 (en) 1997-09-18
ID16224A (id) 1997-09-11
AU2207797A (en) 1997-10-01
MY120693A (en) 2005-11-30
HUP9902698A2 (hu) 1999-11-29
IL126115A0 (en) 1999-05-09
SV1997000018A (es) 1999-01-14

Similar Documents

Publication Publication Date Title
DE69735996D1 (de) Menschlicher bikunin
ID17948A (id) Piridine bersumbu heterosiklik
ATE262512T1 (de) Arylalkanoylpyridazine
ID18010A (id) Oligosakarida termodifikasi
ATE208773T1 (de) Chinoxalindione
NO302786B1 (no) Böyebegrenser
NO983435D0 (no) Aspartylproteaseinhibitorer
ATE353652T1 (de) Östroprogestatives antikonzeptionsmittel
DK0832553T3 (da) Mejetærsker
DE59710984D1 (de) Rotationssprühzerstäuber
DE69710847D1 (de) Beta-Hydroxyasparaginsäurederivate
KR970056542U (ko) 넥타이
SI0891426T1 (sl) Humani bikunin
KR970054675U (ko) 티슈용 케이스
FI104309B1 (fi) Pyörätuoli
SK1470U (sk) Invalidný vozík
BR9602770A (pt) Ataude funebre
ITMO960138A0 (it) Posata
FI3003U1 (fi) Kuormapankka
KR970050917U (ko) 개량 티슈케이스
PT9344T (pt) Cadeira de rodas
KR970053233U (ko) 구두제조용 목형
ZA972084B (en) Human bikunin
ATE267568T1 (de) Epithese
BR7601310U (pt) Microlivro

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0891426

Country of ref document: EP

REN Ceased due to non-payment of the annual fee